Screening for prostate cancer: an updated Cochrane systematic review

• To determine whether screening for prostate cancer reduces prostate cancer‐specific mortality, impact on all‐cause mortality and patient health‐related quality of life.

[1]  R. Dhir.  15-Year Followup of a Population Based Prostate Cancer Screening Study , 2010 .

[2]  O. Ogawa.  Risk Factors for Prostate Cancer , 2004 .

[3]  O. Löfman,et al.  Clinical consequences of screening for prostate cancer: 15 years follow-up of a randomised controlled trial in Sweden. , 2004, European urology.

[4]  P. Walsh,et al.  The development of human benign prostatic hyperplasia with age. , 1984, The Journal of urology.

[5]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[6]  Holman,et al.  Mortality and prostate cancer risk in 19 598 men after surgery for benign prostatic hyperplasia , 1999, BJU international.

[7]  F. Labrie,et al.  Screening decreases prostate cancer mortality: 11‐year follow‐up of the 1988 Quebec prospective randomized controlled trial , 2004, The Prostate.

[8]  U. Norming,et al.  Dihydrotestosterone levels and survival in screening-detected prostate cancer: a 15-yr follow-up study. , 2008, European urology.

[9]  B. G. Blijenberg,et al.  European randomized study of screening for prostate cancer—The Rotterdam pilot studies , 1996, International journal of cancer.

[10]  L. Holmberg,et al.  Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. , 2008, Journal of the National Cancer Institute.

[11]  F. Labrie,et al.  Screening and treatment of localized prostate cancer decreases mortality: First analysis of the first prospective and randomized study on prostate cancer screening , 1999 .

[12]  B. G. Blijenberg,et al.  Screening and prostate-cancer mortality in a randomized European study. , 2009, The New England journal of medicine.

[13]  H. D. de Koning,et al.  Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  David Chia,et al.  Mortality results from a randomized prostate-cancer screening trial. , 2009, The New England journal of medicine.

[15]  P. Walsh,et al.  Radical prostatectomy versus watchful waiting in early prostate cancer. , 2005, The Journal of urology.

[16]  U. Norming,et al.  15-year followup of a population based prostate cancer screening study. , 2009, The Journal of urology.

[17]  F. Labrie,et al.  Screening decreases prostate cancer death: First analysis of the 1988 Quebec Prospective Randomized Controlled Trial , 1999, The Prostate.

[18]  Harry J de Koning,et al.  Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. , 2003, Journal of the National Cancer Institute.

[19]  D. Grignon,et al.  Age and racial distribution of prostatic intraepithelial neoplasia. , 1996, European urology.

[20]  L. Holmberg,et al.  Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial. , 2009, European urology.

[21]  M. Roobol,et al.  Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. , 2002, Urology.

[22]  P C Prorok,et al.  Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. , 2000, Controlled clinical trials.

[23]  T. Wilt,et al.  Screening of prostate cancer. Is it needed? Russian experience , 2006 .

[24]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[25]  Laura Esserman,et al.  Rethinking screening for breast cancer and prostate cancer. , 2009, JAMA.

[26]  W. Catalona.  Prostate-cancer screening. , 2009, The New England journal of medicine.

[27]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[28]  R. Thomson,et al.  Decision aids for people facing health treatment or screening decisions. , 2003, The Cochrane database of systematic reviews.

[29]  O. Löfman,et al.  Repeated screening for carcinoma of the prostate by digital rectal examination in a randomly selected population. , 1992, Acta oncologica.

[30]  Pär Stattin,et al.  Prostate specific antigen for early detection of prostate cancer: longitudinal study , 2009, BMJ : British Medical Journal.

[31]  N. Oakley.  Mortality and prostate cancer risk in 19598 men after surgery for benign prostatic hyperplasia , 2000 .

[32]  F. Hamdy,et al.  Screening for Prostate Cancer , 2006 .

[33]  P. Walsh,et al.  Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. , 2003, The Journal of urology.

[34]  Erik Holmberg,et al.  Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. , 2010, The Lancet. Oncology.